-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Gemini Therapeutics (NASDAQ:GMTX) Shares Down 6.4%
Gemini Therapeutics (NASDAQ:GMTX) Shares Down 6.4%
Gemini Therapeutics, Inc. (NASDAQ:GMTX – Get Rating)'s stock price dropped 6.4% during mid-day trading on Thursday . The company traded as low as $1.52 and last traded at $1.55. Approximately 51,834 shares traded hands during trading, a decline of 72% from the average daily volume of 182,922 shares. The stock had previously closed at $1.65.
Gemini Therapeutics Trading Up 0.6 %
The company has a market cap of $67.38 million, a PE ratio of -1.56 and a beta of -0.12. The business has a fifty day moving average of $1.71 and a 200-day moving average of $1.61.
Get Gemini Therapeutics alerts:Insider Activity at Gemini Therapeutics
In related news, major shareholder Braden Michael Leonard sold 22,500 shares of the business's stock in a transaction dated Wednesday, October 26th. The stock was sold at an average price of $2.09, for a total transaction of $47,025.00. Following the transaction, the insider now owns 247,500 shares in the company, valued at approximately $517,275. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 12.90% of the stock is owned by company insiders.
Institutional Inflows and Outflows
Hedge funds have recently bought and sold shares of the business. MYDA Advisors LLC grew its holdings in shares of Gemini Therapeutics by 215.0% during the 3rd quarter. MYDA Advisors LLC now owns 63,000 shares of the company's stock worth $103,000 after acquiring an additional 43,000 shares during the period. Nantahala Capital Management LLC purchased a new position in shares of Gemini Therapeutics during the 3rd quarter worth approximately $423,000. ExodusPoint Capital Management LP purchased a new position in shares of Gemini Therapeutics during the 3rd quarter worth approximately $85,000. Assenagon Asset Management S.A. grew its holdings in shares of Gemini Therapeutics by 423.2% during the 3rd quarter. Assenagon Asset Management S.A. now owns 82,171 shares of the company's stock worth $135,000 after acquiring an additional 66,467 shares during the period. Finally, Goldman Sachs Group Inc. grew its holdings in shares of Gemini Therapeutics by 80.1% during the 2nd quarter. Goldman Sachs Group Inc. now owns 36,635 shares of the company's stock worth $62,000 after acquiring an additional 16,297 shares during the period. Hedge funds and other institutional investors own 83.40% of the company's stock.About Gemini Therapeutics
(Get Rating)
Gemini Therapeutics, Inc, a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients.
Featured Articles
- Get a free copy of the StockNews.com research report on Gemini Therapeutics (GMTX)
- MarketBeat: Week in Review 12/12 – 12/16
- Which Two Bluechip Tech Companies Have Raised Their Guidance?
- Should You Worry About Elon Musk Selling His Tesla Shares?
- Can Tractor Supply Stock Surge Past Cup-With-Handle Buy Point?
- This is no Time to Buy Lennar but the Time is Coming
Receive News & Ratings for Gemini Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemini Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Gemini Therapeutics, Inc. (NASDAQ:GMTX – Get Rating)'s stock price dropped 6.4% during mid-day trading on Thursday . The company traded as low as $1.52 and last traded at $1.55. Approximately 51,834 shares traded hands during trading, a decline of 72% from the average daily volume of 182,922 shares. The stock had previously closed at $1.65.
雙子座治療公司(Gemini Treateutics，Inc.)股價週四午盤下跌6.4%，最低報1.52美元，尾盤報1.55美元。全天約有51,834股易手，較182,922股的日均成交量下跌72%。該股此前收盤報1.65美元。
Gemini Therapeutics Trading Up 0.6 %
雙子座治療公司股價上漲0.6%
The company has a market cap of $67.38 million, a PE ratio of -1.56 and a beta of -0.12. The business has a fifty day moving average of $1.71 and a 200-day moving average of $1.61.
該公司市值為6738萬美元，本益比為-1.56，貝塔係數為-0.12。該業務的50日移動均線切入位在1.71美元，200日移動均線切入位在1.61美元。
Insider Activity at Gemini Therapeutics
雙子座治療公司的內部活動
In related news, major shareholder Braden Michael Leonard sold 22,500 shares of the business's stock in a transaction dated Wednesday, October 26th. The stock was sold at an average price of $2.09, for a total transaction of $47,025.00. Following the transaction, the insider now owns 247,500 shares in the company, valued at approximately $517,275. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 12.90% of the stock is owned by company insiders.
在相關新聞中，大股東布拉登·邁克爾·倫納德在10月26日星期三的交易中出售了22,500股該公司的股票。該股以2.09美元的平均價格出售，總成交金額為47,025.00美元。交易完成後，這位內部人士現在擁有該公司247,500股，價值約517,275美元。這筆交易是在提交給美國證券交易委員會的一份檔案中披露的，該檔案可以通過美國證券交易委員會網站。12.90%的股份由公司內部人士持有。
Institutional Inflows and Outflows
機構資金流入和流出
About Gemini Therapeutics
關於雙子座治療公司
(Get Rating)
(獲取評級)
Gemini Therapeutics, Inc, a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients.
Gemini治療公司是一家臨床階段精準藥物公司，致力於開發各種治療化合物，用於治療遺傳定義的年齡相關性黃斑變性(AMD)。它的主要候選藥物是GEM103，一種重組形式的人類補體因數H蛋白，用於治療幹性AMD患者。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on Gemini Therapeutics (GMTX)
- MarketBeat: Week in Review 12/12 – 12/16
- Which Two Bluechip Tech Companies Have Raised Their Guidance?
- Should You Worry About Elon Musk Selling His Tesla Shares?
- Can Tractor Supply Stock Surge Past Cup-With-Handle Buy Point?
- This is no Time to Buy Lennar but the Time is Coming
- 免費獲取StockNews.com關於雙子座治療(GMTX)的研究報告
- MarketBeat：回顧一週12/12-12/16
- 哪兩家藍籌科技公司提高了他們的指引？
- 你應該擔心埃隆·馬斯克出售他持有的特斯拉股票嗎？
- 拖拉機庫存能否突破杯柄收購點？
- 現在不是購買Lennar的時候，但時機即將到來
Receive News & Ratings for Gemini Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemini Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《雙子座治療日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對雙子座治療公司和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧